

CORRECTION

Correction: “Noncoding RNA and Alcohol Use Disorder: A Scoping Review of Current Research and Knowledge Gaps”

Deepa Upreti, Rosaline P. Kumar, Justin B.J. Chen, Sneha L. Sonti, Abigail V. Bowring, Sheila W. Green, and Rajesh C. Miranda

Correspondence

Address correspondence concerning this article to Rajesh C. Miranda, Department of Neuroscience and Experimental Therapeutics, Texas A&M School of Medicine, 8447 John Sharp Parkway, Bryan, TX 77807, email: rmiranda@tamu.edu, or to Sheila W. Green, Medical Sciences Library, Texas A&M University Libraries, 202 Olsen Blvd, College Station, TX 77843, email: sgreen@library.tamu.edu.

Publisher's Note

Opinions expressed in contributed articles do not necessarily reflect the views of the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health. The U.S. government does not endorse or favor any specific commercial product or commodity. Any trade or proprietary names appearing in *Alcohol Research: Current Reviews* are used only because they are considered essential in the context of the studies reported herein.

This is a correction to: *Alcohol Res.* 2025; 45(1):06. <https://doi.org/10.35946/arcr.v45.1.06>.

An error appeared in Appendix 4. The text in Row 23 (Zhou, 2018) under column 6 (Key lncRNA Findings) of that table reads: “lncRNA Gm5901 was downregulated in hepatocytes of mouse during alcohol-associated hepatic fibrosis (AHF), and alcohol-treated primary hepatocytes; lncRNA Gm5901 negatively regulated cell migration, reactive oxygen species levels, IL-1beta secretion, collagen I expression, and hepatocytes activation markers; Gm5901 bound miR-27b, miR-23b, and miR-24, reducing their levels and alleviating AHF in mice.”

The correct text should read: “lncRNA Gm5091 was downregulated in hepatocytes of mouse during alcohol-associated hepatic fibrosis (AHF), and alcohol-treated primary hepatocytes; lncRNA Gm5091 negatively regulated cell migration, reactive oxygen species levels, IL-1beta secretion, collagen I expression, and hepatocytes activation markers; Gm5091 bound miR-27b, miR-23b, and miR-24, reducing their levels and alleviating AHF in mice.”